Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEORX(nerx) -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Levy who wrote (575)	2/22/2000 1:04:00 AM
From: RWReeves	Read Replies (1) \| Respond to of 661

Buyout? Not likely at a crappy 2 buck premium to market. Need to pry it out of my cold dead fingers or at least offer 5 bucks more. No, just haul over to your favorite charting program and compare NERX to IMMU. TheraMAB companies (BIOM, CLTR, IMMU, NERX, CRXA) all getting a turn, NERX just took a bit longer to go. I owned IMMU off and on since $1. Long Nerx in a big way. BTW take a look at ALRXF (aka AXO.T). Small Canadian theramab co. I own some of that too, not enough to make it a pump, just trying to find sympathy moves in sectors. RWR